As new therapies enter the treatment landscape for metastatic disease, the role of the oncology nurse becomes even more critical in educating patients about what side effects to look out for and the importance of reporting any adverse events promptly.
Dendreon, the maker of the first FDA-approved immunotherapy for advanced prostate cancer, sipuleucel-T (Provenge), has filed for chapter 11 bankruptcy.
To help clinicians rethink and redesign their practices by moving from a model that is driven by quantity of care to one focused on patients' health outcomes, the Centers for Medicare & Medicaid Services (CMS) will earmark $840 million to improve health outcomes and reduce unnecessary hospitalization and other overutilization of services.
This past Friday, the Centers for Medicare and Medicaid Services (CMS) released nearly 3,000 pages of regulations finalizing 2015 payment rates for various providers and services in the Medicare program, including physicians.
A consensus has emerged among oncology practitioners that palliative care should not be seen as end-of-life care but is best deployed early to help patients and their caregivers manage symptoms throughout the cancer treatment trajectory.
Nearly two-thirds of patients diagnosed with colorectal cancer report experiencing financial burden during their treatment, according to a study from the University of Michigan.
Even as more hospitals seek to acquire medical groups and physician practices, this consolidation leads to higher expenditures through greater use of hospital-based ambulatory services, according to a recent study from the University of California, Berkeley School of Public Health.
City of Hope teams with OncLive to further promote its distinctions and innovations in cancer care. As a member of OncLive's Strategic Partnership program, City of Hope will have the opportunity to promote its state-of-the-art comprehensive cancer center and the center's latest scientific discoveries, treatment and prevention strategies.
The treatment of women with advanced ovarian cancer is set to undergo a substantial transformation, due to an explosion of clinical trials exploring novel treatment options.
Most privately insured Americans between the ages of 18 and 64 are satisfied with their health care plans, but for those enrolled in high-deductible health plans (HDHPs), a different story emerges.
Checkpoint inhibitors targeting the PD-1 receptor and its ligand, PD-L1, are showing efficacy in early-phase clinical trials in urothelial bladder cancer, generating the promise of new therapies for a disease that has not had a significant treatment advance in 30 years.
New therapeutic strategies utilizing triplet regimens for the treatment of patients with HER2-positive metastatic breast cancer (MBC) continue to emerge as an exciting area of development
Spending on 47 currently available oral oncologic drugs has increased from $940 million in the first quarter of 2006 to $1.4 billion in the third quarter of 2011, according to results of a study by Rena M. Conti, PhD, and colleagues at the University of Chicago.
As director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven, Thomas J. Lynch Jr, MD, wears many hats. And, having built a career united around two abiding goals of clinical discovery and personalized patient care, that's just the way he likes it.
Michael J. Hennessy Associates‚ Inc (MJH), a full-service healthcare education, market research, and communications company reaching more than 600,000 healthcare professionals, has acquired CURE Media Group (www.curetoday.com) from McKesson Specialty Health, a division of McKesson Corporation.
Patients with unresectable melanoma had a significant improvement in the odds of survival when treated in first line with a combination of BRAF and MEK inhibitors, as opposed to anti-BRAF monotherapy
All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.
Almost 60% of patients with advanced non–small cell lung cancer experienced tumor shrinkage when treated with the PD-L1 inhibitor pembrolizumab.
Patients with advanced lung cancer had improved appetite, less weight loss, and a significant increase in lean body mass when treated with the ghrelin agonist anamorelin.
Afatinib delayed disease progression for approximately one month longer than chemotherapy and helped prevent painful symptoms from worsening for patients with relapsed or metastatic head and neck squamous cell carcinoma.
For more than 20 years, Klaus Strebhardt, PhD, has been exploring the polo-like kinase (PLK) pathway, including its role in cancer and Plk1-targeted anticancer therapies.
Although the ICD-10 launch was moved to October 1, 2015, vendors and health plans look to be making some progress on the switchover. The same can't be said for physician providers, however.
Myeloma survivors owe much to Robert A. Kyle's reluctance to perform autopsies or to undergo cardiac catheterization.
Treatment advancements for patients with acute myeloid leukemia (AML) are few and far between with marginal gains being made in the form of changes in current standard therapies or supportive care.
Does Medicare coverage for patients with cancer match up to what they actually want covered? There appears to be a mismatch between covered benefits and beneficiary preferences that involves quality of life and financial burden of care, according to a study from Duke University.
Revelations About Cancer Mutations Predate Technological Advances
Increasingly, payers and patients are demanding that hospital-based oncology practices take a patient-centered approach in delivering care, with a specific focus on offering some form of financial assistance services to their patients, according to findings from the Association of Community Cancer Centers' "2014 Trends in Cancer Programs" survey.
Data from a brand new survey addressed some of the emotional issues faced by physicians when treating and delivering a diagnosis of advanced breast cancer.
Terence Friedlander, MD, specializes in understanding the basic biology of genitourinary cancer, in particular cancer of the bladder and prostate, in developing new treatments and studying new ways to overcome treatment resistance.
Sara Hurvitz, MD, highlights key points on the PIK3CA mutation, and addresses several other key topics in the field of breast cancer.